Recombinant factor VIIa (rFVIIa) has of April 2022 been approved by the European Medicines Agency for treatment of severe postpartum haemorrhage. The extended approval is based on one small open-label, non-blinded randomized trial of 84 women from 2015 showing reduced "second line" treatment, but also increased risk of thromboembolism. Systematic use of tranexamic acid and timely coagulation assessment with thromboelastography/rotational thromboelastometry are not applied. Danish and international societies recommend that rFVIIa is reserved as a last option in severe life-threatening cases of postpartum haemorrhage.
|Bidragets oversatte titel||Not Available|
|Tidsskrift||Ugeskrift for Laeger|
|Status||Udgivet - 21 nov. 2022|
- Factor VIIa/therapeutic use
- Postpartum Hemorrhage/drug therapy
- Recombinant Proteins/therapeutic use
- Randomized Controlled Trials as Topic